Eldon C. Mayer III is Director at Eiger BioPharmaceuticals, Inc. (EIGR). They have made 9 open-market trades across 2 companies since 2001, most recently 2023-03-17.
CIK 0001686952
5 open-market purchases totalling $924K since 2001, against 4 sales. Across 5 scored buys the stock is down 1.6% at ninety days, and 3.5 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 20% | 40% |
| Avg Move | +4.0% | -6.9% | -1.6% |
| Alpha | +5.4% | -0.8% | +3.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EIGR | SELL | 2023-03-17 | 2023-03-21 | $1.07 | $5K | -15.4% | -3.8% | -11.3% |
| EIGR | SELL | 2022-03-14 | 2022-03-14 | $5.60 | $9K | +81.0% | +38.7% | +0.0% |
| EIGR | SELL | 2022-01-07 | 2022-01-11 | $4.95 | $8K | -13.2% | -3.4% | +65.8% |
| EIGR | SELL | 2021-01-08 | 2021-01-11 | $11.68 | $20K | -6.2% | +7.5% | -27.8% |
| EIGR | BUY | 2020-01-24 | 2020-01-30 | $13.52 | $68K | -4.3% | -23.9% | -35.0% |
| EIGR | BUY | 2018-11-29 | 2018-11-30 | $10.21 | $41K | +8.0% | -6.0% | +22.1% |
| RIGL | BUY | 2018-09-10 | 2018-09-12 | $3.26 | $326K | +3.1% | -3.1% | -13.8% |
| RIGL | BUY | 2018-08-23 | 2018-08-27 | $2.82 | $282K | +8.1% | +4.4% | -7.4% |
| EIGR | BUY | 2001-11-28 | 2018-11-28 | $9.90 | $208K | +5.2% | -6.0% | +25.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.